AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 101 min read$COO

Cooper Companies Shares Tumble 14% After Q3 Results, Strategic Review

Cooper Companies (COO) shares fell 14% to $54.79 after Q3 results and a strategic review. The board decided to retain CooperSurgical, not sell it. The stock's 52-week range is $51.01 to $89.83.

Original reporting
rttnews.com
Published Sep 10, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 6:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cooper Companies Shares Tumble 14% After Q3 Results, Strategic Review — source image
Source · rttnews.com
Decision brief

The 30-second read

$COOBearishHigh
01

Why it matters

The earnings miss and strategic review decision triggered a sharp sell‑off, indicating weak near‑term outlook.

02

Market read

The stock's 14% plunge highlights immediate trading relevance for short‑term positions.

03

What to watch

Potential hidden cash flow improvements from retaining CooperSurgical may not be reflected yet.

Relevance 8/10Novelty 8/10Timing: same-day release

Background

Cooper Companies (COO) is a U.S. medical‑device firm; the Q3 earnings release included a decision to keep its surgical unit.

Company-level read

Ticker impact

$COOBearishHigh confidence
Context

Cooper Companies reported Q3 results and a strategic review, causing the stock to tumble 14% intraday.

Expected impact

Further downside risk if guidance remains weak; short positions may be favored.

Evidence & confidence

The 14% drop on the day of the earnings release signals fresh, material information that traders can act on immediately.

Market effects

Sector

Medical device sector may see pressure as peers' earnings are compared.

Regional

U.S. market sentiment could dip slightly in healthcare stocks.

Global

Limited to investors tracking U.S. med‑tech equities.

Counterpoint

What could challenge this read

If the strategic review leads to future acquisitions, the dip could be a buying opportunity.

Key entities

  • Company
    Cooper Companies

    Medical device manufacturer reporting Q3 results.

Read at source← All news

Also covered by

3 outlets

Related articles

SEP 10
$COOMedAI 8/10

Why is CooperCompanies Stock Down 15% Today?

CooperCompanies (COO) shares dropped 13.9% after Q3 earnings beat estimates but Q4 guidance fell short of expectations. The company also decided to retain CooperSurgical, removing a potential deal catalyst. U.S. distributor destocking is expected to continue impacting CooperVision's Q4 performance.

aol.com2 min
SEP 10
$COOMedAI 8/10

Why CooperCompanies (COO) Stock Is Trading Lower Today

CooperCompanies (COO) shares fell 13.9% after reporting Q2 revenue of $1.07B, missing estimates. Organic revenue grew 1%, and adjusted EPS of $1.15 beat expectations. The company lowered full-year revenue and EPS guidance. Management decided to retain CooperSurgical, citing valuation issues. William Blair downgraded the stock to Market Perform.

financialcontent.com2 min
SEP 10
$COOMedAI 8/10

Cooper (COO) Q3 2026 Earnings Call Transcript

Cooper Companies (COO) reported Q3 2026 revenue of $1.066B, up 1% organically, with non-GAAP EPS of $1.15, up 4% YoY. Free cash flow hit a record $273M. CooperVision revenue was flat, while CooperSurgical grew 3%. The company guided Q4 revenue to $1.057B-$1.080B and EPS to $1.05-$1.09. Management decided to retain CooperSurgical, citing better shareholder value than current transaction proposals. The company faces near-term revenue pressures from U.S. inventory reductions and macro headwinds in

aol.com2 min
SEP 10
$COOMed

Cooper Companies earnings analysis: questions answered and next catalysts

Cooper Companies (COO) reported Q3 earnings that beat EPS estimates but missed on revenue, leading to a 14.07% drop in share price. Revenue was $1.066B vs. $1.10B estimate, and adjusted EPS was $1.15 vs. $1.12 estimate. Management attributed the revenue miss to inventory destocking and expects recovery in Q4. The company also abandoned the sale of CooperSurgical due to valuation concerns. Next catalysts include Q4 earnings, inventory normalization, and FY2027 guidance.

investing.com7 min
SEP 10
$AEOHigh

Premarket movers: American Eagle, Shoe Carnival slide following results

U.S. stock futures were mixed ahead of inflation data. American Eagle (AEO) shares fell 11% after weak results and flat margin outlook. Shoe Carnival (SCVL) dropped 23.3% on disappointing Q2 results and lowered outlook. Cooper Companies (COO) tumbled 15.3% after a revenue miss and lowered guidance. Alumis (ALMS) rose 6.3% on positive drug data. Culp (CFI) surged 18.8% on strong Q1 results. Vince Holding (VNCE) gained 5.3% after Q2 results.

investing.com3 min